The number of people living with diabetes is rising and is projected to increase sharply around the world. Diabetes is a significant global public health challenge, that when undiagnosed or not adequately addressed, puts people at higher risk of life-threatening complications, such as heart attack, kidney failure, liver disease, and more. Hemoglobin A1c (HbA1c) measures the average blood glucose level over the last 2-3 months, aiding in the diagnosis and monitoring of diabetes.
Learning Objectives:
After attending this webinar, participants will be able to:
- Explain HbA1c testing and its correlation to historical diabetes patients' clinical outcomes studies
- Understand the HbA1c standardization process and the current state of HbA1c measurements
- Analyze potential analytical and biological interferences affecting HbA1c results
Speaker:
Randie R. Little, Ph.D.
National Glycohemoglobin Standardization Program (NGSP) Network Coordinator
Departments of Pathology and Child Health
University of Missouri School of Medicine
Randie R. Little, Ph.D. is a Research Professor in the Departments of Pathology and Anatomical Sciences and Child Health at the University of Missouri and is Director of the Diabetes Diagnostic Laboratory.
Dr. Little is the coordinator of the NGSP network, a member of the NGSP Steering Committee and she coordinates the NIDDK C-peptide Standardization activities. Dr. Little is also the chair of the IFCC Insulin Standardization Work Group. Recent publications include those on the effects of Hb variants on HbA1c measurements, analytical goals for HbA1c measurement and standardization of C-peptide measurements.